Published in Gene Therapy Weekly, April 12th, 2001
The company's lead investigator, Dr. Burkhard Jansen from the University of Vienna, Austria, presented the data at an educational session entitled "Apoptosis in drug development and therapy," which reviewed innovative approaches to triggering cancer cell death.
In his presentation, Jansen reviewed the clinical results on his pilot series of patients, who were treated with Genasense plus a standard drug known as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.